News & updates

Introducing our first LUMC Global PhD candidate: Jeremia J. Pyuza

Created on:


June 21, 2021

Creating new sustainable relationships between the Leiden University Medical Center (LUMC) and international counterparts is one of the core elements incorporated in the LUMC Global strategy. Through multiannual partnerships in (bio)medical research and education, we aim to contribute to global healthcare improvement. We’re therefore very excited to announce our first Global PhD candidate, Jeremia J. Pyuza, who’s at the centre of a newly set-up collaboration between Kilimanjaro Christian Medical Centre (KCMC), Tanzania and the LUMC.

Getting to know Jeremia

Even though he just started his PhD project, Jeremia is no stranger to the LUMC. The African medical doctor and lab scientist first commenced studies at the LUMC through our Half Minor course on Global health. During this time, active discussions on follow-up projects with Professor and Dean Pancras Hogendoorn and Professor Maria Yazdanbakhsh ultimately led to this recently established collaboration between KCMC and the LUMC.

His research project

Now, Jeremia is working on research focused on the role of parasitic infections and different geographical locations on the immune system and vaccination. Tanzania is the second country for the burden of Schistosomiasis after Nigeria in Africa, for example, making research on this subject all the more relevant. From his pilot study, conducted in the Mwanga district Kilimanjaro region in Tanzania, he concluded that Schistosomiasis affects around 50 percent of children. “We are now trying to get a better understanding of how infection and the environment affect the immune system”, says Jeremia. To date, Tanzania is receiving millions of doses of vaccines, and uses a large proportion of its resources to buy and distribute vaccines. However, there are very few studies that evaluate the immunogenicity of vaccines, particularly live ones, in populations living in different geographical areas. “With the current proposal we plan to investigate whether parasites are associated with poor vaccine responses in Tanzania. If they are, we want to identify the mechanisms responsible for blocking vaccine responses, which will allow us to reverse this block and, thus, improve vaccine responses. Therefore, we want to analyze the immune system of those living in rural areas where exposure to parasites is high and compare it to those living in urban areas where burden of these infections is low. We will then compare their response to a vaccination” says Jeremia.

And the young researcher is now at the start of the project. “Right now, I’m trying to get a proper understanding of the subject and the project in general. I’m working on writing a review article on the subject. This will help to see what has already been discovered on the subject and identify where the gaps in our knowledge are. Hopefully we can fill some of them. I’m also working on my research proposal to submit for ethical review in Tanzania after which I will come to the LUMC to learn more on data collection, sample processing, and data analysis”, says Jeremia.

A valuable collaboration

His journey to the LUMC will mark the first of many. Jeremia will travel to the LUMC to use and learn about technology not available at KCMC for his research. He will use the skills gained to continue his research for patients in Tanzania. The LUMC, in turn, will send students of Medicine and Biomedical Sciences to Tanzania to gain knowledge on tropical diseases and parasitic infections not occurring or uncommon in the Netherlands. Jeremia will supervise these students to help them become more rounded professionals and help them gain inadept knowledge not easily available in the Netherlands. Jeremia: “They will be exposed to patients actually suffering from these conditions and see how we treat them. An experience they cannot obtain at home.”

Jeremia leaves us with this concerning his project: “This project is very important and hopefully we can really set our mark for future research and expand knowledge on the subject. Knowledge doesn’t expire. Stimulating more knowledge is, thus, indispensable.” Finally, Jeremia sends his sincere word of thanks to Professor Gilleard Masenga the excutive director KCMC,  Dr Sarah Urassa Director of hospital services KCMC, Professor Sia Msuya a local supervisor, and Dr Elichilia R Shao who will be among teachers for exchange students, for their generous support at the start and continuation of this collaboration.


More news & updates

Background Image Of A Scientist Recording Test Results In A Lab

Janssen COVID-19 vaccine approved for use in EU on March 11

March 11, 2021

The Janssen-Cilag International N.V COVID-19 vaccine has received authorization for emergency use by the European Medicines Agency (EMA) on March 11. Developed with fundamental support from the Molecular Virology group of the Leiden University Medical Centre (LUMC), it is the fourth vaccine to be administered in the European Union. The Netherlands has ordered more than 11 million vaccine doses.

Studying abroad during a pandemic

July 15, 2021

For many students from the LUMC’s academic programmes, studying abroad is an indispensable experience. Doing part of your studies abroad is a special experience, not only because of the sense of adventure of being abroad, also to develop a broader perspective on Life Sciences & Health, a highly international field. So, you can imagine the LUMC’s International Office’s struggle to have to tell students ‘no’ for a study experience abroad in the midst of the corona pandemic. In addition, the many lockdowns worldwide increased the workload dramatically for the International Office. Evelien Hack, Head of the International Office and Sandra van Deursen, senior administrative assistant, share how corona has impacted studying abroad.

Body cells under a microscope. A good illustration as a representation of research of stem cells, cellular therapy and regeneration and many other concepts. 3D illustration

LUMC and Ixaka announce collaboration to advance cell therapy development

March 30, 2021

The Leiden University Medical Center (LUMC) and Ixaka Ltd. have announced a research collaboration on 30 March 2021, to better understand REX-001, Ixaka’s lead cell therapy product. The project will be led by Professor Paul Quax, Head of Experimental Vascular Surgery at the LUMC, to support accelerated development of REX-001 in Phase III clinical trials for the treatment of chronic limb-threatening ischemia (CLTI).

Stay up to date with news, inspirations and events.

© LUMC Global. All rights reserved. Website door philogirl

Contact

Social